Assessing Sino Biopharmaceutical (SEHK:1177) Valuation After New GSK Partnership On Hepatitis B Drug Candidate

Simply Wall St.05-13

Sino Biopharmaceutical (SEHK:1177) has drawn fresh investor attention after subsidiary Chia Tai Tianqing agreed an exclusive partnership with GSK to commercialise bepirovirsen for chronic hepatitis B ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635473240?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-05-13 02:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635473240","market":"sg","top_or_hot":-1,"title":"Assessing Sino Biopharmaceutical (SEHK:1177) Valuation After New GSK Partnership On Hepatitis B Drug Candidate","media":"Simply Wall St.","content":"<div>\n<p>Sino Biopharmaceutical (SEHK:1177) has drawn fresh investor attention after subsidiary Chia Tai Tianqing agreed an exclusive partnership with GSK to commercialise bepirovirsen for chronic hepatitis B ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1177/sino-biopharmaceutical-shares/news/assessing-sino-biopharmaceutical-sehk1177-valuation-after-ne\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Sino Biopharmaceutical (SEHK:1177) Valuation After New GSK Partnership On Hepatitis B Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Sino Biopharmaceutical (SEHK:1177) Valuation After New GSK Partnership On Hepatitis B Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-13 02:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1177/sino-biopharmaceutical-shares/news/assessing-sino-biopharmaceutical-sehk1177-valuation-after-ne><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sino Biopharmaceutical (SEHK:1177) has drawn fresh investor attention after subsidiary Chia Tai Tianqing agreed an exclusive partnership with GSK to commercialise bepirovirsen for chronic hepatitis B ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1177/sino-biopharmaceutical-shares/news/assessing-sino-biopharmaceutical-sehk1177-valuation-after-ne\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ08YR35.GBP","symbol_name":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1177/sino-biopharmaceutical-shares/news/assessing-sino-biopharmaceutical-sehk1177-valuation-after-ne","article_id":"2635473240","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1177/sino-biopharmaceutical-shares/news/assessing-sino-biopharmaceutical-sehk1177-valuation-after-ne","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2635473240","pubTimestamp":1778611767,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Sino Biopharmaceutical (SEHK:1177) has drawn fresh investor attention after subsidiary Chia Tai Tianqing agreed an exclusive partnership with GSK to commercialise bepirovirsen for chronic hepatitis B in mainland China.\nSee our latest analysis for Sino Biopharmaceutical.\nThe partnership news lands after a mixed price run, with the stock up 2.12% on a 1 day share price return and 6.25% over 7 days, yet down 15.37% over 90 days. The 1 year total shareholder return of 52.60% contrasts with weaker...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓","BK4585":"ETF&股票定投概念","LU1829250122.USD":"高盛欧洲核心股票组合Acc","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","GSKH":"GSK plc ADRhedged","GSK.UK":"葛兰素史克","GSK":"葛兰素史克","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","BK4532":"文艺复兴科技持仓","BK1515":"抗疫概念","BK1589":"北水核心资产","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4007":"制药","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","01177":"中国生物制药","BK4588":"碎股"},"translate_title":"在葛兰素史克就乙肝候选药物建立新合作伙伴关系后，评估中国生物制药（SEHK：1177）的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"GSKH":0.6,"GSK.UK":0.6,"01177":0.9,"GSK":1.5},"content_text":"Sino Biopharmaceutical (SEHK:1177) has drawn fresh investor attention after subsidiary Chia Tai Tianqing agreed an exclusive partnership with GSK to commercialise bepirovirsen for chronic hepatitis B in mainland China. See our latest analysis for Sino Biopharmaceutical. The partnership news lands after a mixed price run, with the stock up 2.12% on a 1 day share price return and 6.25% over 7 days, yet down 15.37% over 90 days. The 1 year total shareholder return of 52.60% contrasts with weaker multi year figures and suggests momentum has recently picked up again. If this liver disease story has caught your attention, it could be a good moment to broaden your watchlist using our screener for 121 healthcare AI stocks So with Sino Biopharmaceutical trading at HK$5.78 and flagged as trading at an intrinsic discount of about 65%, is the recent hepatitis B partnership creating a genuine value gap, or has the market already priced in future growth? AdvertisementPreferred P/E of 38.2x: Is it justified? On earnings, Sino Biopharmaceutical trades on a P/E of 38.2x, which sits above both peer and industry averages, even as the share price is at HK$5.78. The P/E multiple compares the current share price with earnings per share and is a quick way to see how much the market is paying for each dollar of profit. For a pharmaceutical group with a mix of established products and active research and development, a higher P/E can reflect expectations for future earnings growth beyond what current profits alone suggest. Here, the stock’s P/E of 38.2x stands well above the Hong Kong pharmaceuticals industry average of 15x and the peer average of 20.4x. This indicates investors are paying a clear premium for Sino Biopharmaceutical’s earnings. That premium is also higher than the estimated fair P/E of 27.2x, a level the market could move toward if expectations and reality start to align more closely. Explore the SWS fair ratio for Sino Biopharmaceutical Result: Price-to-Earnings of 38.2x (OVERVALUED) However, you also need to weigh risks such as any setbacks in bepirovirsen’s progress and Sino Biopharmaceutical’s full revenue reliance on mainland China. Find out about the key risks to this Sino Biopharmaceutical narrative. Another view: DCF suggests a wide discount While the 38.2x P/E points to an expensive stock relative to peers and the industry, the SWS DCF model paints a very different picture. With Sino Biopharmaceutical at HK$5.78 versus an estimated future cash flow value of HK$16.54, the shares are indicated as significantly undervalued. Which lens do you trust more when those signals clash? Look into how the SWS DCF model arrives at its fair value. 1177 Discounted Cash Flow as at May 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Sino Biopharmaceutical for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 223 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps With such mixed signals, it helps to stress test the optimism in the numbers yourself and not just follow the headline reaction. If you want to see what is driving that positive angle, start with the 4 key rewards Looking for more investment ideas? If Sino Biopharmaceutical is on your radar, do not stop there. Widening your search now can help you spot opportunities before everyone else catches on.  Target value opportunities with strong fundamentals by checking companies on the 223 high quality undervalued stocks. Prioritise stability and resilience by reviewing stocks in the 304 resilient stocks with low risk scores. Spot potential early-stage standouts before they become widely followed by scanning the screener containing 543 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635473240","isCrawlerRequest":true}